← Back to patent-cliff list
NLM-001
Tier C — Watch / tradeNLM-001
Millennium Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：SHH
Indications (approved)：Pancreatic cancer, 胰腺导管癌, Basal cell carcinoma
Regional status
US
No progress
2010-10-01
EU
Phase II
2021-09-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NLM-001?
Approved indications include: Pancreatic cancer, 胰腺导管癌, Basal cell carcinoma.
When does the NLM-001 patent expire?
No public expiry year is available for NLM-001 yet; this page updates once verified.
How do I get a quote for NLM-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21